Synopsis: Shares of a pharma player came into focus after announcing a ₹533 crore greenfield facility on 30 acres. Despite 11% growth, margins remained stable with OPM at 22%. Operating profit rose to ₹828 crore, while long-term growth is supported by expansion and MedTech opportunities.
The shares of the generic and specialty pharmaceutical companies are in the spotlight after the company setting up of a greenfield formulations manufacturing facility with an approved investment of upto Rs 533 crores.
With a market capitalization of Rs 62,759.67 crore, the shares of Alkem Laboratories Ltd were trading at Rs 5,249.00 per share, decreasing around 1.86 percent as compared to the previous closing price of Rs 5,348.60 apiece.
Expansion
According to the company filing, Alkem Laboratories’ plan to set up a greenfield formulations facility in Ujjain reflects its strategic focus on expanding manufacturing capacity and strengthening its domestic footprint. The phased investment of up to ₹533 crore indicates a long-term growth approach while managing capital allocation efficiently. Securing 30 acres of land in an industrial zone also provides scalability for future expansion. This move is likely to enhance production capabilities, support new product launches, and improve supply chain efficiency over time.
Financials
The company delivered 11% revenue growth, increasing from ₹3,374 crore to ₹3,737 crore, reflecting healthy business momentum. However, net profit rose just 2% from ₹641 crore to ₹653 crore, indicating margin pressure. This divergence suggests rising costs or limited operating leverage despite strong top-line performance during the quarter.
Over the past year, the company’s operating performance remained relatively stable with a positive bias. Operating profit increased from ₹759 crore in Dec 2024 to ₹828 crore in Dec 2025, reflecting improved operational strength. Meanwhile, OPM moderated slightly from 23% to 22%, indicating largely stable margins despite cost pressures, supporting consistent profitability.
Alkem’s entry into the MedTech space appears strategically aligned with a large and growing global market, expected to reach $870 billion by 2030. Strong entry barriers, customer loyalty, and innovation support long-term competitiveness. In India, supportive policies, high import dependence, and cost advantages create significant opportunities, positioning the company for sustainable growth and margin expansion.
Alkem Laboratories is a leading Indian pharmaceutical company with a strong presence in domestic and international markets. It focuses on branded generics, acute and chronic therapies, and exports to key regions. The company is also expanding into new segments like MedTech, strengthening its long-term growth and innovation capabilities.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma Stock in Focus After Co. to Invest ₹533 Cr to Set Up Greenfield Manufacturing Facility appeared first on Trade Brains.